
|Peer-Reviewed|December 23, 2020
- January 2021
- Volume 27
- Issue 1
Supplemental Material: Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel
Supplemental materials for article examining the incidence and impact of chemotherapy induced peripheral neuropathy on clinical and economic outcomes in women with metastatic breast cancer initiating intravenous paclitaxel/nab-paclitaxel.
Advertisement
Articles in this issue
almost 5 years ago
ASH 2020: Clinical Updatesalmost 5 years ago
ASH 2020: COVID-19 and Hematologyalmost 5 years ago
ASH 2020: CAR T-Cell Therapy Updatesalmost 5 years ago
ASH 2020: The Next Wavealmost 5 years ago
2020 SABCS: Topics in Precision OncologyNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
'Tis the Season: SABCS 2025 to Highlight Latest Advances Across the Breast Cancer Continuum
2
Once-Monthly Maridebart Cafraglutide Shows Up to 16% Weight Loss
3
EPCORE FL-1: Adding Epcoritamab to R2 Delivers “New Benchmark” in Second-Line Follicular Lymphoma
4
Azacitidine/Venetoclax Combo Data Challenge Chemo in Fit Patients With AML
5












































